Article thumbnail

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer

By K K Mauland, J Trovik, E Wik, M B Raeder, T S Njølstad, I M Stefansson, A M Øyan, K H Kalland, T Bjørge, L A Akslen and H B Salvesen
Topics: Clinical Study
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). 55: 74–108 S a l v e s e nH B ,C a r t e rS L ,M a n n e l q v i s tM ,D u t tA ,G e t zG ,S t e f a n s s o nI M ,R a e d e r M B ,S o sM L ,E n g e l s e nI B ,T r o v i kJ ,W i kE ,G r e u l i c hH ,B oT H ,J o n a s s e
  2. (1993). 98: 1582–1585 Mikuta JJ
  3. (2005). Endometrial cancer. Lancet 366: 491–505
  4. (2009). Gynecol Oncol 15: 10–17 Cancer Registry of Norway
  5. (2001). Med Assoc 98: 1814–1822
  6. (2010). Role of progesterone in endometrial cancer. Semin Reprod Med 28: 81–90 Lindemann K, Vatten LJ,
  7. (2006). Salvesen HB (2008b) GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.